Drug Development by Government Pharmaceutical Organization. Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand
|
|
|
- Ashlee Lindsey
- 5 years ago
- Views:
Transcription
1 Drug Development by Government Pharmaceutical Organization Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand 20August 2012
2 GPO s Profile GPO was established in GPO is a state enterprise under the Ministry of Public Health At present, GPO manufactures and sells more than 300 items of pharmaceutical products including biological products, with more than 2,500 staff.
3 Vision To be a leader in pharmaceutical products and medical supplies beneficial and essential to the Thai society and fairness
4 Mission To manufacture, sell and supply pharmaceutical products and medical supplies with a aim to achieve world-class standard To develop business to ensure competitiveness and selfsustainability To maintain price level of pharmaceutical products and medical supplies for the Thai society to ensure people s accessibility To research and develop new pharmaceutical products, and medical supplies to respond to the need and necessity of the Thai society
5 Drug Development Product Formulation Overview
6 Preformulation Physicochemical characteristics of the drug Pharmaceutical factors Physiological factors
7 1. Physicochemical characteristics of the drug Molecular structure Solubility Organoleptic property Purity Crystalline and Polymorph Hygroscopic Bulk density Particle size and shape Melting point Surface properties (charge) Drug pka Partition coefficient (Log P) Chemical degradation Powder flow property
8 Particle size analysis X-ray diffractometry Differential scanning calorimetry
9 2. Pharmaceutical factors Factors related to formulation (excipients) i.e. Lactose, Microcrytalline cellulose Dosage form Compatibility study Manufacturing process
10 Compatibility study Initial 30 days 30º C,75%RH 40º C, 75%RH Drug +Diluent (1:1) Drug+Binder (1:1) or (10:1) Drug +Disintegrant (1:1) or (10:1) Drug +Lubricant (1:1) or (15:1) Drug +Coloring agent (1:1) or (20:1) Powder characteristics (i.e. Color and Impurity) Powder characteristics (i.e. Color and Impurity) Powder characteristics (i.e. Color and Impurity) Powder characteristics (i.e. Color and Impurity) Powder characteristics (i.e. Color and Impurity)
11 Pharmaceutical Equipments For Solid dosage form i.e. Powder, Tablet, Capsule, Lozenge, Suppository Liquid dosage form i.e. Solution, Syrup, Tincture, Emulsion, Suspension Semi-solid dosage from i.e. Cream, Paste, Ointment
12 Cube mixer V-shape mixer
13 Double Cone Mixer (for powder blending)
14 Wet Granulation Hobart mixer Horizontal mixer
15 Wet Granulation High speed mixer
16 Dryer Tray dryer Fluidized bed dryer
17 Compression Machine Rotary tablet compression machine
18 Film coater
19 Pelletization Extruder and Spheronizer Fluidized bed coater
20 Demonstrations on different types of extruders ZSE 18 HP-PH Pelletizer (configuration of vacuum conveyor according to pressure requirements)
21 Semisolid dosage form Vacuum Homogenizer Homogenizer
22 2. Physiological factors Protein and tissue binding Regional ph Intestinal permeation Hepatic metabolism Mucus Gastric and intestinal transit Presence of food Individual variation (gender, race, age and disease state)
23 Physical and Chemical Studies 1. Disintegration test 2. Dissolution test 3. Stability studies
24 Dissolution Profile Levofloxacin 500 mg tablet dissolution profiles Percent labeled amount dissolved Reference product S Time (mins)
25 Stability studies Container Closure System 1. Primary packaging HDPE bottle Strip pack (Nylon/Al/PVC) Alu/Alu pack (Nylon/Al/PVC) Blister pack - Duplex (PVC/PVDC) - Triplex (PVC/PE/PVDC ) - PVC/ACLAR 2. Secondary packaging (Boxes)
26 Stability study a) Evaluated temperature study b) Stability under high humidity condition c) Photolytic stability d) Stability to oxidation
27 Stability study Accelerated Stability Study (40ºC, 75%RH) Pass 6 months Long term Stability Study (30ºC, 75%RH) Pass 12 months (Estimation shelf-life 2 years) Real time study up to 60 months Long term Stability Study (25ºC, 60%RH) Real time study up to 60 months
28 Stability Chamber
29 Pilot batch Scale up batch (at least 2 pilot batches) Stability data generation for registration Bioequivalence study Pharmacokinetic and Clinical studies
30 Technological Capabilities - Tablets Direct mixing Unit operation Equipment R&D Pilot Plant Manufacturing Screening Vibratory sifter Vibratory sifter Vibratory sifter Comil (Lab Model) Quadro, Canada Comil Quadro, Canada Comil Quadro, Canada Blending Bin Blender (10 /20L ) Bin Blender (75/165 L) Bin Blender (300/600L)
31 Technological Capabilities - Tablets Wet granulation Unit operation Equipment R&D Pilot Plant Manufacturing A. High Shear Granulator Rapid Mixer Granulator (5-25 L) Rapid Mixer Granulator (40 L) Planetary Mixer (2-4L) Rapid Mixer Granulator (250 & 600 L) Planetary Mixer (60 L & 120 L) B. Top Spray Granulator Fluid Bed Processor (5 L) Fluid Bed Processor (125 & 500 L)
32 Pharmacokinetic and Clinical Study No Projects Organization Weeks Study of Safety and Efficacy of a Simplified Fixed-Dose Combination of Stavudine, Lamivudine and Nevirapine (GPO-VIR ) for the Treatment of Advanced HIV-Infected Patients 2. Clinical, virological and immunological response of HIVinfected children to highly active antiretroviral treatment 3. A 48 week, randomized, open-label, 2 arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after initiating rifampin containing antituberculous therapy Faculty of Medicine Siriraj Hospital Mahidol University Faculty of Medicine Chiangmai University HIV-NAT, Thai Red Cross AIDS Research Centre
33 Pharmacokinetic and Clinical Study (cont.) No Projects Organization 4. A Phase I/II comparative Pharmacokinetic study of the fixed-dose combination (FDC) of stavudine (d4t), lamivudine (3TC) and nevirapine (NVP) as GPO-VIR S7 pediatric chewable tablets versus the individual liquid formulation in HIV-infected children 6 months to < 13 years of age in Thailand 5. A 72-week randomized clinical trial comparing the safety and efficacy of three initial antiretroviral regimens-gpo- VIR S30 (D4T/3TC/NVP) for 24 weeks followed by GPO- VIR Z250 (AZT/3TC/NVP) vs GPO-VIR Z250 vs TDF/FTC/NVP Faculty of Medicine Siriraj Hospital Mahidol University HIV-NAT, Thai Red Cross AIDS Research Centre
34 Pharmacokinetic and Clinical Study (cont) No Projects Organization 6. A Phase I/II comparative Pharmacokinetic study of the fixed-dose combination (FDC) of zidovudine (AZT), lamivudine (3TC) and nevirapine (NVP) as GPO-VIR Z30 pediatric tablets versus the individual liquid formulation in HIV-infected children 5 months to < 13 years of age in Thailand 7. Therapeutic drug monitoring safety and efficacy of the generic lopinavi/ritonavir tablets 200/50 mg in Thai HIVinfected Patient Faculty of Medicine Siriraj Hospital Mahidol University HIV-NAT, Thai Red Cross AIDS Research Centre
35 Pharmacokinetic and Clinical Study (cont) No Projects Organization 8. Treatment outcome and safety of zidovudine/lamivudine/nevirapine fixed-dose combination in HIV-infected Thai patients HIV-NAT, Thai Red Cross AIDS Research Centre 9. Pharmacokinetic study and safety monitoring of tenofovir including once daily antiretroviral regimen in HIVinfected children with viral suppression Faculty of Medicine Siriraj Hospital Mahidol University
36 Pharmacokinetic and Clinical Study (cont) No Projects Organization 10. Initiation of a once daily regimen of tenofovir, lamivudine and efavirenz after 4 weeks versus 12 weeks of tuberculosis treatment in HIV-1 infected patients Bamrasnaradura Infectious Diseases Institute 11. Comparative study between entecavir and tenofovir in the treatment of chronic hepatitis B infection in Thai patients Chulabhorn Hospital
37 R & D Pilot Plant BE Study Stability data generation Manufacturing Stage I 2 months Stage II 4 6 months Stage III 1 2 months Stage IV 12 months Stage V Product Preformulations Prototype & lab-scale Scale-up & Stability data Tech. transfer Identification Development Exhibit Batch generation for to Mfg & Process & Allocation registration Validation Development Timelines ( upto Stage III ) Simple Products : 7 10 Months Complex Products : Months Timelines
38 New ARV Rungsit Plant Total area : 20,000 Sq.mt. Capacity around : 2,335 million tablets and capsule/year Apply for WHO pre-qualification
39 THANK YOU AND ANY QUESTIONS Please visit us at
18 July 2009 The 1st International Workshop on HIV Pediatrics Cape Town, South Africa
A Novel Pediatric Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), Nevirapine (NVP): Pharmacokinetics and Safety in HIV-Infected Thai Children 18 July 2009 The 1st International Workshop
SCIENTIFIC DISCUSSION. Efavirenz
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredient (API): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1 Introduction This is an application for a CHMP Scientific Opinion in accordance with Article 58 of Regulation (EC) No 726/2004, in the context of cooperation with the World Health
List of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary, which are included in parts
WHOPAR. SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
Unigel TM Case Study: Extending Soft Gelatin Capsule Benefits to Novel Fixed Dose Combinations
Unigel TM Case Study: Extending Soft Gelatin Capsule Benefits to Novel Fixed Dose Combinations Diego Monterroza, H. M. Sc, Corporate Manager, R&D Procaps S.A. Stand # 30A46 OUTLINE Fixed Dose Combinations
LAB.2. Tablet Production Methods
LAB.2 Tablet Production Methods Dry methods Direct compression Dry granulation Wet methods Wet granulation Regardless whether tablets are made by direct compression or granulation, the first step, milling
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
Abacavir (as sulfate) 300 mg tablets WHOPAR part 6 May 2016 (Hetero Labs Ltd), HA575
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
SCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
Tablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good
TABLET PRODUCTİON Tablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good quality at high standards. Based on preformulation
Biopharmaceutics Dosage form factors influencing bioavailability Lec:5
Biopharmaceutics Dosage form factors influencing bioavailability Lec:5 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 09/01/2019
Table 1. Coating Parameters
ACRYL-EZE Aqueous Acrylic Enteric System Application Data Performance Characteristics of Acryl-EZE, Aqueous Acrylic Enteric System Eudragit L1-55 is a copolymer of methacrylic acid and ethyl acrylate (1:1
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1 INTRODUCTION This application has been submitted to the EMEA for the CHMP to issue a scientific opinion in accordance with Article 58 of Regulation (EC) No 726/2004, in the context
Food supplement manufacture
Food supplement manufacture Nick Bennett BSc. RNutr April 2018 1 Introduction There are many different product formats available Liquids, powders, tablets, capsules etc Many different types of machine
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Rifampicin/Isoniazid 150mg/75mg filmcoated Tablets Svizera
SCIENTIFIC DISCUSSION. Darunavir
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi
Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi Presented by: Nandita Sugandhi M.D. 6 th International Workshop on HIV Pediatrics July
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
DISCIPLINE RECORD/ COURSE / SEMINAR DESCRIPTION
Universitatea de Medicină şi Farmacie Grigore T. Popa Iaşi Comisia pentru asigurarea calităţii DISCIPLINE RECORD/ COURSE / SEMINAR DESCRIPTION 1. Information about the program UNIVERSITY: GRIGORE T. POPA
SCIENTIFIC DISCUSSION. AkuriT-3 Tablets*
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
IATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose
LubriTose Mannitol Michael Crowley, Director of R&D, Excipients
LubriTose Mannitol Michael Crowley, Director of R&D, Excipients Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY 13815 PH 315-802-5970 Michael.Crowley@Kerry.com 2
KING KHALID UNIVERSITY
KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SCHEDULE MALE SECTION SOLID DOSAGE FORMS FOR PHARMACEUTICAL SCIENCES/CLINICAL PHARMACY BY PROF DR MOHAMED FATHY Academic Session
Innovations in Pharmaceuticals and Pharmacotherapy.
Innovations in Pharmaceuticals and Pharmacotherapy www.innpharmacotherapy.com IPP eissn: 2321 323X Original Article Preformulation Studies for development of a generic capsule formulation of Celecoxib
Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products
57. Starch Convention, Detmold, April 26-28, 2006 K.-J. Steffens Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products Starches, Pharmaceutical Applications _ Starches
Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, User s Manual
Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, 2005 User s Manual Index 1. Overview 2. Scale-Up Assumptions 3. Procurement Assumptions 4. Clinical Assumptions 5.
Pediatric ARV Working Group Dosing Recommendations
Pediatric ARV Working Group Dosing Recommendations Overall Goals To develop pediatric weight band dosing for ARVs that would simplify dosing and produce therapeutic drug exposure Recommend dosing strengths
Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation
Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation Workshop on Paediatric Formulations For Assessors in National Regulatory Agencies
REVISION OF MONOGRAPH ON TABLETS. Tablets
March 2011 REVISION OF MONOGRAPH ON TABLETS Final text for addition to The International Pharmacopoeia This monograph was adopted by the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical
Principals and Dosage Forms in the Therapy Modified Drug Release. Institute of Pharmaceutical Technology and Biopharmacy
Principals and Dosage Forms in the Therapy Modified Drug Release Institute of Pharmaceutical Technology and Biopharmacy Dosage forms Definition: Dosage forms are the means by which drug molecules are delivered
Efavirenz/Emtricitabine/ WHOPAR part 6 August 2011 Tenofovir disoproxil fumarate 600mg/200mg/300mg Tablets (Matrix Lab.
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
Mylan Laboratories Limited F-4 & F-12, Malegaon MIDC, Sinnar Nashik Maharashtra State, India
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
REGULATORY PERSPECTIVE. Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore
1 REGULATORY PERSPECTIVE Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore Contents 2 1. Role of Dissolution Testing in Generic Drug Approval 2. Dissolution Testing Recommendation for Solid Oral
EP B1 (19) (11) EP B1 (12) EUROPEAN PATENT SPECIFICATION
(19) (11) EP 1 864 677 B1 (12) EUROPEAN PATENT SPECIFICATION (4) Date of publication and mention of the grant of the patent: 02.01.08 Bulletin 08/01 (1) Int Cl.: A61K 38/ (06.01) A61K 9/ (06.01) A61K 31/39
CONSIDERATION OF THE END USER AND THE LIMITATIONS DURING THE ORAL ADMINISTRATION DRUG DESIGN: CHALLENGE IN DIFFERENT AGE GROUPS
CONSIDERATION OF THE END USER AND THE LIMITATIONS DURING THE ORAL ADMINISTRATION DRUG DESIGN: CHALLENGE IN DIFFERENT AGE GROUPS Adriana Quiroga Technical Manager Colorcon Latin South America 0 Summary
A Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS OVERVIEW OF PRESENTATION Introduction : lessons learnt Availability ; implications of making paediatric formulations available Remaining challenges in
University of Sulaimani School of Pharmacy Dept. of Pharmaceutics Third level - Second semester
University of Sulaimani School of Pharmacy Dept. of Pharmaceutics Third level - Second semester 5/21/2017 Pharmaceutical Compounding, Dr. rer. nat. Rebaz Ali 1 Outlines Why rectal or vaginal route? Suppository
Content Uniformity of Direct Compression tablets
Content Uniformity of Direct Compression tablets Contents 1 Summary 4 2 Introduction 4 3 The role of drug particle size 4 4 The role of mixing strategy 5 5 The role of excipients 5 6 Laboratory data 6
SCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): International Nonproprietary Name: Pharmaco-therapeutic
CHAPTER-2 DRUG AND POLYMER PROFILES
57 CHAPTER-2 DRUG AND POLYMER PROFILES 58 2.1 DRUG PROFILES 2.1.1 Lamivudine (3TC) 85 US FDA approval date: November 1995 Structural formula of lamivudine Physicochemical properties of lamivudine 1. Description
Principals and dosage forms of pharmaceutics
Principals and dosage forms of pharmaceutics Part II. Semisolid dosage forms: ointments, creams, gels, pastes, suppositories, pessaries 2017 Dr. Farkas, Gyula Pharmaceutical Propedeutics Institute of Pharmaceutical
AUSTRALIAN MADE CAMPAIGN LIMITED
AUSTRALIAN MADE CAMPAIGN LIMITED PHARMACEUTICALS AND COMPLEMENTARY HEALTHCARE PRODUCTS - COMPLIANCE POLICY May 2018 Summary Made Campaign Limited (AMCL) is the t-for-profit organisation which administers
Priority essential medicines: identifying products. Dr Suzanne Hill September 2010
Priority essential medicines: identifying products Dr Suzanne Hill September 2010 The problem looks like this Robertson, Forte, Trapsida & Hill. Bull WHO 2009 Robertson, Forte, Trapsida & Hill. Bull WHO
FORMULATION CHOICE. How and why they are chosen. Dr Andy Fowles On behalf of ECPA Specification Expert Group
FORMULATION CHOICE How and why they are chosen Dr Andy Fowles On behalf of ECPA Specification Expert Group Topics Why formulate? How to identify formulation options Drivers Principle formulation type overview
Public Assessment Report. Scientific discussion. Tevaltan comp. Film-coated tablets 80 mg/12.5 mg and 160 mg/25 mg. Valsartan and hydrochlorothiazide
Public Assessment Report Scientific discussion Tevaltan comp. Film-coated tablets 80 mg/12.5 mg and 160 mg/25 mg Valsartan and hydrochlorothiazide DK/H/1524/001-002/DC This module reflects the scientific
SCIENTIFIC DISCUSSION
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Product name: TAMIFLU Procedure No: EMEA/H/C/402/X/44 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London,
Large scale production
Large scale production Rotary capsule machine: This machine has two, side-by-side cylinders in each of which half-moulds are cut. These cylinders, like the rollers of a mangle, rotate in contrary direction
Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations
49th Annual Meeting Non-Sterile Compounding/ Sunil Jambhekar, B. Pharm., M.S., Ph.D Professor, Pharmaceutical Sciences LECOM Bradenton, School of Pharmacy Bradenton, FL 34211 Disclosure I do not have a
Technical Transfer- A tablet process transfer case study. Presented by Jonathan King 4 July, 2016
Technical Transfer- A tablet process transfer case study Presented by Jonathan King 4 July, 2016 What is a technical transfer? Technical transfer is about enabling someone else to do what you are able
67 Years of Leadership in Pharmacy. A Journey of Continuous Improvement
67 Years of Leadership in Pharmacy A Journey of Continuous Improvement September 2012 GALENIKA A.D. IS The only Serbian state-owned pharmaceutical company Manufacturer of generic drugs its manufacturing
DRY SYRUPS SWAPNA.M. Ist semester DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY, WARANGAL SEMINAR BY
DRY SYRUPS SEMINAR BY SWAPNA.M M.PHARMACY Ist semester DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY, WARANGAL CONTENTS DEFINITION CHARACTERISTICS OF SUSPENSIONS
Define the terms biopharmaceutics and bioavailability.
Pharmaceutics Reading Notes Define the terms biopharmaceutics and bioavailability. Biopharmaceutics: the area of study concerning the relationship between the physical, chemical, and biological sciences
Invitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
Contract Manufacturing Fluid Bed Technology. Drying. Spray granulation. Coating. Agglomeration. Instantization.
Contract Manufacturing Fluid Bed Technology Drying. Spray granulation. Coating. Agglomeration. Instantization. Multifunctional fluid bed processor State-of-the-art fluid bed technology for a diversity
Medicines recommended to prevent and manage the priority diseases at the community and health facility level
s recommended to prevent and manage the priority diseases at the community and health facility level Shamim Qazi Department of Child and Adolescent Health and Development Global Causes of Child Deaths
CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
Excipient Considerations for Continuous Manufacturing Implementation
Excipient Considerations for Continuous Manufacturing Implementation FDA-PQRI Conference March 22-24, 2017 David R. Schoneker Director of Global Regulatory Affairs Email: dschoneker@colorcon.com 1 Continuous
US A United States Patent (19) 11 Patent Number: 5,635,209 Groenewoud et al. 45 Date of Patent: Jun. 3, 1997
US005635209A United States Patent (19) 11 Patent Number: Groenewoud et al. 45 Date of Patent: Jun. 3, 1997 (54) STABILIZED COMPOSITION OF LEVOTHYROXNE SODIUM MEDICATION 4,585,652 4,818,531 4/1986 Miller
CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION
CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION LEARNING OBJECTIVES The objectives of this unit are to: Understand the formulation of solid dosage form. Understand the characteristic
PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
Public Assessment Report. Scientific discussion. Amlodipine/Valsartan Apotex 5 mg/80 mg, 5 mg/160 mg and 10 mg/160 mg, film-coated tablets
C Public Assessment Report Scientific discussion Amlodipine/Valsartan Apotex 5 mg/80 mg, 5 mg/160 mg and 10 mg/160 mg, film-coated tablets (amlodipine besilate/valsartan) NL/H/3447/001-003/DC Date: 13
UNIT 2 SOLID AND LIQUID DOSAGE FORMS
UNIT 2 SOLID AND LIQUID DOSAGE FORMS Solid and Liquid Structure 2.1 Introduction Objectives 2.2 Solid Tablets Capsules 2.3 Liquid Advantages of Liquid Disadvantages of Liquid Classification of Liquid Monophasic
Somnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
SCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
Public Assessment Report. Scientific discussion. Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/ /MR
Public Assessment Report Scientific discussion Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/001-002/MR Date: 26 May 2014 This module reflects the scientific discussion
PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION
PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION 1 PHARMACEUTICS Pharmaceutics is the science of dosage form design. The general area of study concerned with the formulation, manufacture, stability, and
Partner with the Global Leader in Drug Delivery Systems
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems Loughborough, United Kingdom Manufacturing Facility Experts at Commercializing Innovation 3M: Transforming New Ideas into
International Journal of Innovative Pharmaceutical Sciences and Research
International Journal of Innovative Pharmaceutical Sciences and Research www.ijipsr.com FORMULATION AND EVALUATION OF MODIFIED REALEASE CAPSULES OF BUDESONIDE 1 K.Veera Kumari*, 2 Dr. Appa Rao, 3 Dr.Shaik.Harun
UNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS. November 3-4, WHO Headquarters, Geneva, EB Room
UNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS November 3-4, 2004 WHO Headquarters, Geneva, EB Room Summary Background In 2003, more than 5 million people
3. Drug or plant or excipients profile
3. Drug or plant or excipients profile 3. 1 Analysis of Reference Listed Drug (RLD) Product ABILIFY (aripiprazole) 3.1.1 Clinical The Reference Listed Drug (RLD) is Brand ABILIFY (aripiprazole) Tablets
Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1
Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1 ASAHI KASEI CHEMICALS CORPORATION CEOLUS R&D DEPARTMENT 1 CONTENTS General
Public Assessment Report. Scientific discussion. Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets.
Public Assessment Report Scientific discussion Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets (tadalafil) NL/H/3634/001-004/DC Date: 24 May 2017 This module reflects the scientific
Public Assessment Report. Scientific discussion. Celecoxib Apotex 100 mg and 200 mg, capsules, hard (celecoxib) NL/H/2760/ /DC
Public Assessment Report Scientific discussion Celecoxib Apotex 100 mg and 200 mg, capsules, hard (celecoxib) NL/H/2760/001-002/DC Date: 29 April 2014 This module reflects the scientific discussion for
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
Pharmaceutical Preparation For Internal Use
Pharmaceutical Preparation For Internal Use 1. Solid Preparations (Tablet, Capsule, Pill) 2. Liquid Preparations (Aqua, Syrup, Elixir, Extract, Liquor, Emulsion, Mixture, Infusion, Decoction). 3. Powder
Principles of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
<1151> Pharmaceutical Dosage Forms and <1152> Animal Drugs for Use in Animal Feeds
Pharmaceutical Dosage Forms and Animal Drugs for Use in Animal Feeds Will Brown Veterinary Drugs Stakeholder Forum February 19-20, 2014 Development of a Compendial Taxonomy and Glossary for
Direct Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series)
Technical Data Direct Compression Ranitidine Formulation Direct Compression Formulation Using Starch 15 with Ranitidine HCl (15 mg) Tablets, Film Coated with Opadry II (5F Series) INTRODUCTION Ranitidine
Summary Public Assessment Report. Generics. Pregabalina Biofarmoz PT/H/1292/ /DC
Summary Public Assessment Report Generics 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, capsules, hard (Pregabalin) Summary PAR Generics 1/11 Summary Public Assessment Report Generics Pregabalin 25 mg, 50 mg, 75
FLORITER. New Technology for Innovative Formulation Design.
FLORITER New Technology for Innovative Formulation Design www.tomitaph.co.jp FLORITE Dramatically Change Your Formulation FLORITE is synthetic Calcium Silicate with exceptional liquid absorbency and excellent
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article FORMULATION DEVELOPMENT AND EVALUATION OF IMMEDIATE RELEASE BILAYER TABLETS OF TELMISERTAN AND HYDROCHLOROTHIAZIDE
PEPFAR A US Government Program That is Helping to Keep Millions Alive Around the World
PEPFAR A US Government Program That is Helping to Keep Millions Alive Around the World George Lunn Office of New Drug Quality Assessment Food and Drug Administration A Short History of AIDS 1981 First
3.1 Background. Preformulation Studies
Preformulation Studies 3.1 Background Delivery of any drug requires a suitable dosage form to get optimum therapeutic effects. The development of such dosage forms fundamental properties of the drug molecule
Designed and manufactured specifically for pharmaceutical capsule filling
EXCIPIENTS Designed and manufactured specifically for pharmaceutical capsule filling Simple formulation Superior flow and weight uniformity Clean and efficient processing This document is valid at the
NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant
EXCIPIENTS STARCH 1500 Proven and Trusted Excipient for Performance and Versatility Effective and economical disintegrant Excellent stability for moisture sensitive drugs Manufactured exclusively for the
Easy, fast and reliable!
Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. s film coating products are one-step coating systems for pharmaceutical
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES Cape Winelands Anova Conference 2013 Worcester Lindsay Wilson 3 June 2013 What is a fixed dose combination [FDC]? Pharmaceutical formulation
FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD
Int. J. Chem. Sci.: 6(3), 2008, 1270-1275 FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD K. P. R. CHOWDARY, P. TRIPURA SUNDARI and K. SURYA
Challenges and solutions for moisture sensitive API formulation
Challenges and solutions for moisture sensitive API formulation Introduction Today, formulators are looking for alternative processes to reformulate existing products or to formulate New Chemical Entities
To organise lecture series by experts drawn from Industry and academia in the relevant areas of training.
CSIR-IIIM Skill Development Programme Current Good Manufacturing Practices (cgmp) of Botanicals/ Herbal Drugs/Phytopharmaceuticals (Three Months PG Certificate Course) Introduction CSIR- Indian Institute